Truvestments Capital’s Cardlytics CDLX Stock Holding History

Truvestments Capital’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10	Closed	-$3K	–	219
2019 Q3	$3K	Buy	+10	New	+$3.21K	﹤0.01%	622

Other funds holding CDLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Truvestments Capital's CDLX Position: Q4 2019 in Review

Truvestments Capital sold out of Cardlytics (CDLX) in Q4 2019, closing a stake of 10 shares — an estimated $3K sold.

Truvestments Capital first reported a position in CDLX in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 156 funds tracked by Wall St. Rank hold CDLX as of Q4 2019.

Truvestments Capital reported no remaining Cardlytics position as of Q4 2019 after selling out during the quarter.
Truvestments Capital sold 10 Cardlytics shares in Q4 2019, an estimated $3K.
Truvestments Capital first reported a position in Cardlytics in Q3 2019 and held it in 1 quarter.
Truvestments Capital's Cardlytics position peaked at $3K in Q3 2019.
156 funds tracked by Wall St. Rank held Cardlytics as of Q4 2019.

Based on Truvestments Capital's 13F filing for Q4 2019, filed 29 Jan 2020.